Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection

Experimental Biology and Medicine

Volumn 222, Issue 2, 1999, Pages 157-163

  Clarkson, Edward D ^a   Edwards Prasad, Judith ^a   Freed, Curt R ^a   Prasad, Kedar N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NESTIN; NEURON SPECIFIC ENOLASE; NEUROTOXIN; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; DOPAMINERGIC NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; BRAIN; CELL DIFFERENTIATION; CELL SURVIVAL; CLONE CELLS; DOPAMINE; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GROWTH SUBSTANCES; INSULIN-LIKE GROWTH FACTOR I; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDOPAMINE; RATS; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0032741629     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.1999.d01-126.x     Document Type: Article

References (22)

1. Marshall JF, Understedt U. Striatal efferent fibers play a role in maintaining rotational behavior in the rat. Science 198:62-64, 1977.
2. Richards JB, Sabol KE, Freed CR. Unilateral dopamine depletion causes bilateral deficits in conditioned rotation in rats. Pharmacol Biochem Behav 36:217-223, 1990.
3. Mytilineou C, Cohen G. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. Science 225:529-531, 1984.
4. Cohen G, Mytilineou C. Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 35:237-242, 1985.
5. Björklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177:555-560, 1990.
6. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204:643-647, 1979.
7. Dunnett SB, Hernandez TD, Summerfield A, Jones GH, Arbuthnott G. Graft-derived recovery from 6-OHDA lesions: Specificity of ventral mesencephalic graft tissues. Exp Brain Res 71:411-424, 1988.
8. Bakay RA, Fiandaca MS, Barrow DL, Schiff A, Collins DC. Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. Appl Neurophysiol 48:358-361, 1985.
9. Fine A, Hunt SP, Oertel WH, Chong PN, Bond A, Waters C, Temlett JA, Annett L, Dunnett S, Jenner P, Marsden CD. Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered Parkinsonian by 1-methyl-4-phenyl-1,2,3,6-terahydropyridine. Prog Brain Res 78:479-189, 1988.
10. Taylor JR, Elsworth JD, Roth RH, Sladek JR Jr., Collier TJ, Redmond DE. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: A comparison with other types of grafts as controls. Exp Brain Res 85:335-348, 1991.
11. Sladek JR Jr., Collier TJ, Haber SN, Deutch AY, Elsworth JD, Roth RH, Redmond DE. Reversal of Parkinsonism by fetal nerve cell transplants in primate brain. Ann N Y Acad Sci 495:641-657, 1987.
12. Adams FS, La Rosa FG, Kumar S, Edwards-Prasad J, Kentroti S, Vernadakis A, Freed CR, Prasad KN. Characterization and transplantation of two neuronal cell lines with dopaminergic properties. Neurochem Res 21:619-627, 1996.
13. Clarkson ED, La Rosa FG, Edwards-Prasad J, Weiland DA, Witta SE, Freed CR, Prasad KN. Improvement of neurological deficits in 6-hydroxydopamine lesioned rats following transplantation with allogeneic SV40 large T-antigen gene-induced immortalized dopamine cells. Proc Natl Acad Sci U S A 95:1265-1270, 1998.
14. Prasad KN, Carvalho E, Kentroti S, Edwards-Prasad J, Freed CR, Vernadakis A. Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue. In Vitro Cell Dev Biol 30:596-603, 1994.
15. Prasad KN, Clarkson ED, La Rosa FG, Hovland AR, Edwards-Prasad J, Freed CR. Transplantation of dopamine neurons. In: Marwah J, Teitelbaum H, Eds. Advances in Neurodegenerative Disorders Vol. 1: Parkinson's Disease. Scottsdale, AZ: Prominent Press, pp93-112, 1998.
16. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132, 1993.
17. Cass WA. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 16:8132-8139, 1996.
18. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672:104-111, 1995.
19. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM. GDNF protection against 6-OHDA: Time dependence and requirement for protein synthesis. J Neurosci 17:7111-7118, 1997.
20. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, Horellou P. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94:8818-8823, 1997.
21. Opacka-Juffry J, Ashworth S, Hume SP, Martin D, Brooks DJ, Blunt SB. GDNF protects against 6-OHDA nigrostriatal lesion: In vivo study with microdialysis and PET. Neuroreport 7:348-352, 1995.
22. Pietz K, Odin P, Funa K, Lindvall O. Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. Neurosci Lett 204:101-104, 1996.